354 related articles for article (PubMed ID: 27992443)
1. Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD.
du Plessis J; Korf H; van Pelt J; Windmolders P; Vander Elst I; Verrijken A; Hubens G; Van Gaal L; Cassiman D; Nevens F; Francque S; van der Merwe S
PLoS One; 2016; 11(12):e0166048. PubMed ID: 27992443
[TBL] [Abstract][Full Text] [Related]
2. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease.
du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S
Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579
[TBL] [Abstract][Full Text] [Related]
3. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
4. An assessment of bacterial overgrowth and translocation in the non-alcoholic fatty liver of patients with morbid obesity.
Domper Bardají F; Gil Rendo A; Illescas Fernández-Bermejo S; Patón Arenas R; Hernández Albújar A; Martín Dávila F; Murillo Lázaro C; Sánchez Alonso M; Serrano Dueñas M; Sobrino López A; Ramírez Esteso F; Martín Fernández J
Rev Esp Enferm Dig; 2019 Apr; 111(4):294-300. PubMed ID: 30896956
[TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis.
Ruiz AG; Casafont F; Crespo J; Cayón A; Mayorga M; Estebanez A; Fernadez-Escalante JC; Pons-Romero F
Obes Surg; 2007 Oct; 17(10):1374-80. PubMed ID: 18000721
[TBL] [Abstract][Full Text] [Related]
6. Association between endotoxemia and histological features of nonalcoholic fatty liver disease.
Kitabatake H; Tanaka N; Fujimori N; Komatsu M; Okubo A; Kakegawa K; Kimura T; Sugiura A; Yamazaki T; Shibata S; Ichikawa Y; Joshita S; Umemura T; Matsumoto A; Koinuma M; Sano K; Aoyama T; Tanaka E
World J Gastroenterol; 2017 Jan; 23(4):712-722. PubMed ID: 28216979
[TBL] [Abstract][Full Text] [Related]
7. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
8. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease.
Pang J; Xu W; Zhang X; Wong GL; Chan AW; Chan HY; Tse CH; Shu SS; Choi PC; Chan HL; Yu J; Wong VW
Aliment Pharmacol Ther; 2017 Jul; 46(2):175-182. PubMed ID: 28464257
[TBL] [Abstract][Full Text] [Related]
9. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
10. Bacterial Lipopolysaccharide, Lipopolysaccharide-Binding Protein, and Other Inflammatory Markers in Obesity and After Bariatric Surgery.
Tuomi K; Logomarsino JV
Metab Syndr Relat Disord; 2016 Aug; 14(6):279-88. PubMed ID: 27228236
[TBL] [Abstract][Full Text] [Related]
11. Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children.
Nier A; Engstler AJ; Maier IB; Bergheim I
PLoS One; 2017; 12(9):e0183282. PubMed ID: 28880885
[TBL] [Abstract][Full Text] [Related]
12. Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease.
Arias-Loste MT; Iruzubieta P; Puente Á; Ramos D; Santa Cruz C; Estébanez Á; Llerena S; Alonso-Martín C; San Segundo D; Álvarez L; López Useros A; Fábrega E; López-Hoyos M; Crespo J
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834919
[TBL] [Abstract][Full Text] [Related]
13. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
[TBL] [Abstract][Full Text] [Related]
14. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
15. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
[TBL] [Abstract][Full Text] [Related]
16. Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease.
Wada N; Takaki A; Ikeda F; Yasunaka T; Onji M; Nouso K; Nakatsuka A; Wada J; Koike K; Miyahara K; Shiraha H; Yamamoto K; Okada H
Hepatol Int; 2017 Jan; 11(1):115-124. PubMed ID: 27826704
[TBL] [Abstract][Full Text] [Related]
17. Hepatic TLR4 signaling in obese NAFLD.
Sharifnia T; Antoun J; Verriere TG; Suarez G; Wattacheril J; Wilson KT; Peek RM; Abumrad NN; Flynn CR
Am J Physiol Gastrointest Liver Physiol; 2015 Aug; 309(4):G270-8. PubMed ID: 26113297
[TBL] [Abstract][Full Text] [Related]
18. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
[TBL] [Abstract][Full Text] [Related]
19. Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.
Du SX; Lu LL; Geng N; Victor DW; Chen LZ; Wang C; Yue HY; Xin YN; Xuan SY; Jin WW
Lipids Health Dis; 2017 Dec; 16(1):228. PubMed ID: 29197393
[TBL] [Abstract][Full Text] [Related]
20. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance.
Fujimoto M; Uemura M; Nakatani Y; Tsujita S; Hoppo K; Tamagawa T; Kitano H; Kikukawa M; Ann T; Ishii Y; Kojima H; Sakurai S; Tanaka R; Namisaki T; Noguchi R; Higashino T; Kikuchi E; Nishimura K; Takaya A; Fukui H
Alcohol Clin Exp Res; 2000 Apr; 24(4 Suppl):48S-54S. PubMed ID: 10803780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
